Skip to content
Open access

Naphthalimide-based andrographolide nanoplatform suppresses ccRCC via targeting the HIF-2α/VEGF signaling axis

Sep 2026 · Arabian Journal of Chemistry · pp. 1-10 · 0 citations · 28 references

TL;DR

A naphthalimide-based multifunctional nanoplatform was developed as a drug delivery system for andrographolide (AG) to improve its therapeutic specificity and provide a potential nanocarrier strategy for targeting the HIF-2α/VEGF signaling axis in ccRCC.

Abstract

Constitutive activation of hypoxia-inducible factor-2α (HIF-2α) is a central oncogenic driver in clear cell renal cell carcinoma (ccRCC). In this work, a naphthalimide-based multifunctional nanoplatform was developed as a drug delivery system for andrographolide (AG) to improve its therapeutic specificity. The resulting system (NAI-1@AG) enabled intracellular delivery of AG and reduced ccRCC cell viability. Mechanistic studies showed that AG-loaded nanoparticles downregulated HIF-2α transcription, accompanied by decreased expression of its downstream target VEGF, as confirmed by qRT-PCR and ELISA analyses. Compared with free AG and non-targeted formulations, targeted AG-loaded nanoparticles showed improved anti-proliferative activity, suggesting enhanced pathway-specific inhibition. The nanoplatform also possesses ratiometric fluorescence sensing capability for tryptophan as an auxiliary function. Overall, this system provides a potential nanocarrier strategy for targeting the HIF-2α/VEGF signaling axis in ccRCC.

Read PDF

Similar papers

Open access Nov 2026

Targeting ELF3 with Biomimetic Nanotherapy Sensitizes PDAC to Gemcitabine via GSDME-mediated Pyroptosis.

Pancreatic ductal adenocarcinoma (PDAC) continues to be a lethal malignancy with limited effective treatment strategies due to modest intrinsic response to systemic chemotherapy. Moreover, the dense, fibrotic stroma and poor vasculature of pancreatic tumors severely restrict drug penetration and therapeutic efficacy. T...

Zoya Iqbal, Xin Zhang, Yi-Kai Chen et al. · 0 citations
Open access Oct 2026

Dual-Targeting Nanomicelles Co-Loading Sorafenib and Artesunate Combats Hepatocellular Carcinoma via the Synergistically Enhanced Ferroptosis Strategy.

Collectively, the organelle-specific targeting combined with co-delivery of synergistic drug pairs represents a promising strategy for combating malignancies and provides a blueprint for the rational design of multifunctional nanosystems.

Wang-Jing Lu, Juan Yang, J. Mi et al. · 0 citations
Open access Nov 2026

Niflumic Acid-Loaded Aspasomes as a Repurposed Nanoplatform: Antitumor Effects and Modulation of PI3K/AKT/mTOR Pathway-Related Molecular Markers in Solid Ehrlich Carcinoma-Bearing Mice

Background/Objectives: Breast cancer remains a major global health challenge, with the PI3K/AKT/mTOR signaling axis playing a key role in tumor progression. Drug repurposing offers an efficient approach to cancer therapeutics. Niflumic acid (NIF), a selective cyclooxygenase-2 (COX-2) inhibitor, has demonstrated antipro...

M. M. Mostafa, S. M. Abd El-Halim, Mira Magdy William et al. · 0 citations
Open access Oct 2026

A biomimetic dual-targeting nanoplatform enhancing pyroptosis and chemosensitization for precision therapy of diffuse large b-cell lymphoma

To elucidate the role of SHP-2 in regulating pyroptosis through the TXNIP‑NLRP3 inflammasome axis in diffuse large B‑cell lymphoma (DLBCL) and to evaluate the therapeutic efficacy and safety of a SHP099‑loaded B‑cell membrane–CD20 aptamer dual‑targeting biomimetic nanoplatform (SHP099@Bmem‑AptCD20). SHP-2...

Jing-Xuan Lian, Xiao-Hui Duan, Wen-Jie Chen et al. · 0 citations
Oct 2026

Construction of a mitotane delivery system based on γ-cyclodextrin metal organic framework and its enhanced anti-tumor activity.

Adrenocortical carcinoma (ACC) is an aggressive cancer with an urgent need for more effective and safer therapies. Mitotane (MT), has its clinical utility compromised by poor aqueous solubility and low oral bioavailability. In response, a novel nano-delivery platform was fabricated by encapsulating MT into γ-cyclodextr...

Ze-Chen Yan, Ge-Ping Wu, Yu Wang et al. · 0 citations
Sep 2026

Targeted dual degradation of GPC-3 and VEGFR with multivalent DNA nanoflower-based LYTACs for hepatocellular carcinoma therapy.

While targeted therapies for hepatocellular carcinoma (HCC) have advanced, their clinical benefits remain constrained by limited efficacy, off-target toxicity, and the frequent emergence of drug resistance and recurrence. To address these challenges, we developed a multivalent DNA nanoflower-based dual-targeting LYTAC...

Ping Zhou, Jin-Zhi Zang, Jia-Xuan Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.